EOLS
Evolus, Inc. Common Stock
$6.36
-0.47%
2026-05-08
About Evolus, Inc. Common Stock
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Key Fundamentals
Forward P/E
24.00
EPS (TTM)
$-0.66
Revenue Growth (YoY)
6.7%
Profit Margin
-14.4%
Beta
1.29
Market Cap
$421.5M
Avg Volume (10D)
1.2M
Recent Breakout Signals
No recent breakout signals detected for EOLS.
Recent Price Range (60 Days)
60D High
$6.70
60D Low
$3.86
Avg Volume
1.1M
Latest Close
$6.36
Get breakout alerts for EOLS
Sign up for Breakout Scanner to receive daily notifications when EOLS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Evolus, Inc. Common Stock (EOLS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors EOLS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. EOLS operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.